期刊文献+

实时谐波超声造影对肝门胆管癌的诊断价值 被引量:8

The value of contrast-enhanced harmonic ultrasound for hilar cholangiocarcinoma
原文传递
导出
摘要 目的:探讨实时谐波超声造影对肝门胆管癌的诊断价值。方法:30例病理证实的肝门胆管癌病例,分析病灶的增强时间、增强强度及增强方式,并比较造影前后病灶的清晰显示率。结果:肝门胆管癌平均在17.3s病灶开始增强,25.0s时增强达峰值,64.3s时回声已表现为低于周围肝实质。在门脉期及延迟期分别有50.0%(15/30)及93.3%(28/30)表现为低回声。73.3%(22/30)的病灶增强方式表现为整体增强。造影后,病灶清晰显示率从造影前的23.3%(7/30)提高到93.3%(28/30),差异有统计学意义。结论:实时谐波超声造影可显著提高病灶的清晰显示率,对于指导临床选择手术方式有重要意义。 Objective To evaluate the value of contrast-enhanced ultrasound (CEUS) in hilar cholangiocarcinoma. Methods Thirty cases of hilar cholangiocarcinoma confirmed by pathology performed CEUS,and the enhancement parameters of time,intensity and styles were observed. The clearly displaying rate was compared before and after CEUS. Results The lesions were medially enhanced at 17.3 second,and peak intensity arrived at 25.0 second, hypoechoic enhancement appeared at 64.3 second. The hypoechoic lesions were 50.0 % (15/30) and 93.3 % (28/30) compared with the liver parenchyma in portal vein phase and delayed phase, respectively. The most common enhancement style was homogeneous. The clearly displaying rate of the lesions was significantly improved from 23.30% (7/30) to 93.3%(28/30) after administering the contrast media. Conclusions CEUS could significantly improve the displaying rate of hilar cholangiocarcinomas,and have significant value for selecting appropriate therapy in clinic.
出处 《中华超声影像学杂志》 CSCD 2007年第8期681-684,共4页 Chinese Journal of Ultrasonography
关键词 超声检查 造影剂 胆管肿瘤 Klatskin肿瘤 Ultrasonography Contrast media Bile duct neoplasms Klatskin's tumor
  • 相关文献

参考文献10

二级参考文献59

  • 1黄志强.肝门部胆管癌外科治疗面临的问题与出路[J].中华实验外科杂志,2004,21(7):773-775. 被引量:78
  • 2徐辉雄,吕明德,谢晓燕,刘广健,徐作峰,郑艳玲,梁瑾瑜,黄蓓.肝细胞性肝癌超声造影的增强模式——低机械指数连续实时成像技术的应用研究[J].中国超声医学杂志,2005,21(2):126-129. 被引量:25
  • 3Lillemoe KD, Cameron JL. Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach [ J ]. J Hepatobiliary Pancreat Surg, 2000, 7(2):115-121.
  • 4Otto G, Romaneehsen B, Lotichius MH, et al. Hilar cholangiocarcinoma: respectability and radieality after routine diagnostic image[J].J Hepatobiliary Pancreat Surg, 2004, 11(5):310-318.
  • 5Chamberlain RS, Blumgart LH, Hilar cholangiocarcinoma:a review and commentary[J ]. Ann Surg Oncol, 2000, 7( 1 ) ; 55-66.
  • 6D' Angelica MI, Jarnagin WR, Blurngart LH. Resectable hilar cholangiocarciaoma: surgical treatment and long - term outcome [ J ]. Surg Today, 2004, 34( 11 ) : 885-890.
  • 7Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma[ J ]. Surgical Oncology, 2005,14 (2):59-74.
  • 8Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19 - 9 in the diagnoses of cholangiocarcinoma in patients without primary schrosing cholangitis[ J ]. Am J Gastroenteml, 2000, 95( 1 ) :204-207.
  • 9Levy C, Lymp J, Angulo P, et al. The value of serum CA19 - 9 in predicting cholangiocarcinoma in patients with primary selerosing cholangitis [ J ]. Digestive Diseases and Sciences, 2005, 50 (9) : 1734-1740.
  • 10Zervos EE, Osborne D, Goldin SB, et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach[J]. Am J Surg, 2005, 190(5):810-815.

共引文献134

同被引文献74

引证文献8

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部